Pharmacokinetic considerations for antibody drug conjugates

Pharmaceutical Research

Volumn 29, Issue 9, 2012, Pages 2354-2366

  Lin, Kedan ^a   Tibbitts, Jay ^a  

^a GENENTECH INC   (United States)

Author keywords

Antibody drug conjugates (ADCs); Optimization; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ANTIBODY CONJUGATE; BRENTUXIMAB VEDOTIN; CALICHEAMICIN; CALICHEAMICIN CMD 193 ANTIBODY CONJUGATE; CALICHEAMICIN HU3S193 ANTIBODY CONJUGATE; MONOMETHYLAURISTATIN E ANTIBODY CONJUGATE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE ANTIBODY; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; VEDOTIN;

ANTIBODY AFFINITY; ANTIBODY COMBINING SITE; ANTIBODY ENGINEERING; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIBODY STRUCTURE; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNITY; COMPLEX FORMATION; DRUG ABSORPTION; DRUG CONJUGATION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG METABOLISM; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; IMMUNOGENICITY; MOLECULAR MODEL; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROCESS OPTIMIZATION; REVIEW; TISSUE DISTRIBUTION;

ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOCONJUGATES;

EID: 84866735537     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0800-y     Document Type: Review

References (81)

1. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J. 2008;14:154-69.
2. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat Rev. 2006;5:147-59.
3. Waldmann TA. Immunotherapy: Past, present and future. Nat Med. 2003;9:269-77.
4. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer. 2001;1:118-29.
5. Burris 3rd HA, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE, Michaelson RA, Girish S, Amler L, Zheng M, Chu YW, Klencke B, O'Shaughnessy JA. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011;29:398-405.
6. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Janne PA. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:1039-43.
7. Kustova Y, Espey MG, Sung EG, Morse D, Sei Y, Basile AS. Evidence of neuronal degeneration in C57B1/6 mice infected with the LP-BM5 leukemia retrovirus mixture. Mol Chem Neuropathol. 1998;35:39-59.
8. Reider PJ, Roland DM. The alkaloids. In: Brossi A, editor. Vol. 23, New York: Academic; 1984.
9. LoRusso PM, Weiss D, Guardino E, Girish S, Sliwkowski MX. Trastuzumab emtansine: A unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res. 2011;17:6437-47.
10. Kovtun YV, Audette CA, Mayo MF, Jones GE, Doherty H, Maloney EK, Erickson HK, Sun X, Wilhelm S, Ab O, Lai KC, Widdison WC, Kellogg B, Johnson H, Pinkas J, Lutz RJ, Singh R, Goldmacher VS, Chari RV. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res. 2010;70: 2528-37.
11. Chamarthy MR, Williams SC, Moadel RM. Radioimmunotherapy of non-Hodgkin's lymphoma: From the 'magic bullets' to 'radioactive magic bullets'. Yale J Biol Med. 2011;84:391-407.
12. Horning SJ. Future directions in radioimmunotherapy for B-cell lymphoma. Semin Oncol. 2003;30:29-34.
13. Elgqvist J, Andersson H, Back T, Hultborn R, Jensen H, Karlsson B, Lindegren S, Palm S, Warnhammar E, Jacobsson L. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)Atlabeled monoclonal antibody MX35. J Nucl Med. 2005;46:1907-15.
14. Sharkey RM, Goldenberg DM. Cancer radioimmunotherapy. Immunotherapy. 2011;3:349-70.
15. Steiner M, Neri D. Antibody-radionuclide conjugates for cancer therapy: Historical considerations and new trends. Clin Cancer Res. 2011;17:6406-16.
16. Wu AM, Senter PD. Arming antibodies: Prospects and challenges for immunoconjugates. Nat Biotechnol. 2005;23:1137-46.
17. Zhu H, Baxter LT, Jain RK. Potential and limitations of radioimmunodetection and radioimmunotherapy with monoclonal antibodies. J Nucl Med. 1997;38:731-41.
18. Ingram I. FDA approves brentuximab vedotin for Hodgkin lymphoma and systemic anaplastic large-cell lymphoma. Oncology (Williston Park) 2011;25:904.
19. Lowenberg B, Beck J, Graux C, van Putten W, Schouten HC, Verdonck LF, Ferrant A, Sonneveld P, Jongen-Lavrencic M, von Lilienfeld-Toal M, Biemond BJ, Vellenga E, Breems D, de Muijnck H, Schaafsma R, Verhoef G, Dohner H, Gratwohl A, Pabst T, Ossenkoppele GJ, Maertens J. Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: Results of a multicenter phase 3 study. Blood. 2010;115:2586-91.
20. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93:2645-68.
21. Singh R, Erickson HK. Antibody-cytotoxic agent conjugates: Preparation and characterization. Methods Mol Biol. 2009;525: 445-67. xiv.
22. Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, Kissler KM, Bernhardt SX, Kopcha AK, Zabinski RF, Meyer DL, Francisco JA. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10:7063-70.
23. Wang L, Amphlett G, Blattler WA, Lambert JM, Zhang W. Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci. 2005;14:2436-46.
24. Sun X, Widdison W, Mayo M, Wilhelm S, Leece B, Chari R, Singh R, Erickson H. Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism. Bioconjug Chem; 2011.
25. McDonagh CF, Kim KM, Turcott E, Brown LL, Westendorf L, Feist T, Sussman D, Stone I, Anderson M, Miyamoto J, Lyon R, Alley SC, Gerber HP, Carter PJ. Engineered anti-CD70 antibodydrug conjugate with increased therapeutic index. Mol Cancer Ther. 2008;7:2913-23.
26. Junutula JR, Bhakta S, Raab H, Ervin KE, Eigenbrot C, Vandlen R, Scheller RH, Lowman HB. Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs. J Immunol Methods. 2008;332:41-52.
27. Dornan D, Bennett F, Chen Y, Dennis M, Eaton D, Elkins K, French D, Go MA, Jack A, Junutula JR, Koeppen H, Lau J, McBride J, Rawstron A, Shi X, Yu N, Yu SF, Yue P, Zheng B, Ebens A, Polson AG. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood. 2009;114:2721-9.
28. McDonagh CF, Turcott E, Westendorf L, Webster JB, Alley SC, Kim K, Andreyka J, Stone I, Hamblett KJ, Francisco JA, Carter P. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng Des Sel. 2006;19:299-307.
29. Stephan JP, Chan P, Lee C, Nelson C, Elliott JM, Bechtel C, Raab H, Xie D, Akutagawa J, Baudys J, Saad O, Prabhu S, Wong WL, Vandlen R, Jacobson F, Ebens A. Anti-CD22-MCC-DM1 and MCMMAF conjugates: Impact of assay format on pharmacokinetic parameters determination. Bioconjug Chem. 2008;19:1673-83.
30. Sanderson RJ, Hering MA, James SF, Sun MM, Doronina SO, Siadak AW, Senter PD, Wahl AF. in vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res. 2005;11:843-52.
31. Xie H, Audette C, Hoffee M, Lambert JM, Blattler WA. Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice. J Pharmacol Exp Ther. 2004;308:1073-82.
32. Girish S, Gupta M, Wang B, Lu D, Krop IE, Vogel CL, Burris Iii HA, Lorusso PM, Yi JH, Saad O, Tong B, ChuYW, Holden S, Joshi A. Clinical pharmacology of trastuzumab emtansine (T-DM1): An antibody-drug conjugate in development for the treatment ofHER2-positive cancer. Cancer Chemother Pharmacol. 2012;69:1229-40.
33. Drug Approval Package ADCEREIS (brentuximab vedotin). http://wwwaccessdatafdagov/drugsatfda-docs/nda/2011/125388-adcetris-toccfm; 2011.
34. Korth-Bradley JM, Dowell JA, King SP, Liu H, Berger MS. Impact of age and gender on the pharmacokinetics of gemtuzumab ozogamicin. Pharmacotherapy. 2001;21:1175-80.
35. YounesA, BartlettNL, Leonard JP, KennedyDA, LynchCM,Sievers EL, Forero-Torres A. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363:1812-21.
36. Advani A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gine E, Gisselbrecht C, KettererN, Nasta S, Rohatiner A, Schmidt-Wolf IG, Schuler M, Sierra J, Smith MR, Verhoef G, Winter JN, Boni J, Vandendries E, Shapiro M, Fayad L. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: Results of a phase I study. J Clin Oncol. 2010;28:2085-93.
37. Xu K, Liu L, Saad OM, Baudys J, Williams L, Leipold D, Shen B, Raab H, Junutula JR, Kim A, Kaur S. Characterization of intact antibody-drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography-mass spectrometry. Anal Biochem. 2011;412:56-66.
38. Leipold D, Moore H, Jumbe S, Baudys J, Saad O, Mai E, Wong W, Jay Tibbitts J. Development of a pharmacokinetic model examining trastuzumab-MCC-DM1, MCC-DM1 and DM1 in normal rats. AACR Meeting Abstracts. Oct 2007; 2007.
39. Sapra P, Stein R, Pickett J, Qu Z, Govindan SV, Cardillo TM, Hansen HJ, Horak ID, Griffiths GL, Goldenberg DM. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clin Cancer Res: Official J Am Assoc Cancer Res. 2005;11:5257-64.
40. Boswell CA, Mundo EE, Zhang C, Bumbaca D, Valle NR, Kozak KR, Fourie A, Chuh J, Koppada N, Saad O, Gill H, Shen BQ, Rubinfeld B, Tibbitts J, Kaur S, Theil FP, Fielder PJ, Khawli LA, Lin K. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats. Bioconjug Chem. 2011;22:1994-2004.
41. Scott AM, Tebbutt N, Lee FT, Cavicchiolo T, Liu Z, Gill S, Poon AM, Hopkins W, Smyth FE, Murone C, MacGregor D, Papenfuss AT, Chappell B, Saunder TH, Brechbiel MW, Davis ID, Murphy R, Chong G, Hoffman EW, Old LJ. A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen. Clin Cancer Res. 2007;13:3286-92.
42. Herbertson RA, Tebbutt NC, Lee FT, MacFarlane DJ, Chappell B, Micallef N, Lee ST, Saunder T, Hopkins W, Smyth FE, Wyld DK, Bellen J, Sonnichsen DS, Brechbiel MW, Murone C, Scott AM. Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers. Clin Cancer Res. 2009;15:6709-15.
43. Henry MD, Wen S, Silva MD, Chandra S, Milton M, Worland PJ. A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res. 2004;64:7995-8001.
44. Rupp U, Schoendorf-Holland E, Eichbaum M, Schuetz F, Lauschner I, Schmidt P, Staab A, Hanft G, Huober J, Sinn HP, Sohn C, Schneeweiss A. Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: Final results of a phase I study. Anti-Cancer Drugs. 2007;18:477-85.
45. Tijink BM, Buter J, de Bree R, Giaccone G, Lang MS, Staab A, Leemans CR, van Dongen GA. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res. 2006;12:6064-72.
46. Tolcher AW, Ochoa L, Hammond LA, Patnaik A, Edwards T, Takimoto C, Smith L, de Bono J, Schwartz G, Mays T, Jonak ZL, Johnson R, DeWitte M, Martino H, Audette C, Maes K, Chari RV, Lambert JM, Rowinsky EK. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: A phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol. 2003;21:211-22.
47. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blattler WA, Lambert JM, Chari RV, Lutz RJ, Wong WL, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68:9280-90.
48. Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, Parsons-Reponte KL, Tien J, Yu SF, Mai E, Li D, Tibbitts J, Baudys J, Saad OM, Scales SJ, McDonald PJ, Hass PE, Eigenbrot C, Nguyen T, Solis WA, Fuji RN, Flagella KM, Patel D, Spencer SD, Khawli LA, Ebens A, Wong WL, Vandlen R, Kaur S, Sliwkowski MX, Scheller RH, Polakis P, Junutula JR. Conjugation site modulates the in vivo stability and therapeutic activity of antibodydrug conjugates. Nat Biotechnol. 2012;30:184-9.
49. Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K, Lutz RJ, Goldmacher VS, Blattler WA. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 2006;66:4426-33.
50. Mould DR, Green B. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: Concepts and lessons for drug development. BioDrugs: Clinical immunotherapeutics, biopharmaceuticals and gene therapy 2010;24:23-9.
51. Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeuticmonoclonal antibodies. Drug Discov Today. 2006;11:81-8.
52. Pastuskovas CV, Mallet W, Clark S, Kenrick M, Majidy M, Schweiger M, Van Hoy M, Tsai SP, Bennett G, Shen BQ, Ross S, Fielder P, Khawli L, Tibbitts J. Effect of immune complex formation on the distribution of a novel antibody to the ovarian tumor antigen CA125. Drug Metab Dispos. 2010;38:2309-19.
53. Lovdal T, Andersen E, Brech A, Berg T. Fc receptor mediated endocytosis of small soluble immunoglobulin G immune complexes in Kupffer and endothelial cells from rat liver. J Cell Sci. 2000;113(Pt 18):3255-66.
54. Alley SC, Zhang X, Okeley NM, Anderson M, Law CL, Senter PD, Benjamin DR. The pharmacologic basis for antibodyauristatin conjugate activity. The Journal of pharmacology and experimental therapeutics; 2009.
55. Braeckman RA, editor. Pharmacokinetics and pharmacodynamics of protein therapeutics. NY: Marcel Dekker; 2000.
56. Erickson HK, Widdison WC, Mayo MF, Whiteman K, Audette C, Wilhelm SD, Singh R. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem. 2010;21:84-92.
57. Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL, Senter PD, Alley SC. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res. 2010;16:888-97.
58. Sutherland MS, Sanderson RJ, Gordon KA, Andreyka J, Cerveny CG, Yu C, LewisTS, MeyerDL, Zabinski RF,Doronina SO, Senter PD, Law CL, Wahl AF. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem. 2006;281:10540-7.
59. Austin CD, Wen X, Gazzard L, Nelson C, Scheller RH, Scales SJ. Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates. Proc Natl Acad Sci USA. 2005;102:17987-92.
60. Alley SC, Benjamin DR, Jeffrey SC,OkeleyNM, MeyerDL, Sanderson RJ, Senter PD. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem. 2008;19:759-65.
61. Baillie TA, Cayen MN, Fouda H, Gerson RJ, Green JD, Grossman SJ, Klunk LJ, LeBlanc B, Perkins DG, Shipley LA. Drug metabolites in safety testing. Toxicol Appl Pharmacol. 2002;182:188-96.
62. Smithand DA, Obach RS. Metabolites in safety testing (MIST): Considerations of mechanisms of toxicity with dose, abundance, and duration of treatment. Chem Res Toxicol. 2009;22:267-79.
63. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA. The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos. 2003;31:815-32.
64. FDA. Guidance for industry: In vivo drug metabolism/drug interaction studies-study design, data analysis, and recommendations for dosing and labeling. In: DHHS, editor. Rockville, MD: U.S. Food and Drug Administration; 1999.
65. FDA. Guidance for industry: Drug metabolism/drug interaction studies in the drug development process: Studies in vitro. In: DHHS, editor. Rockville, MD:U.S. Food and Drug Administration; 1997.
66. Lu D, Girish S, Theil F, Joshi A. Pharmacokinetic and pharmacodynamic-based drug interactions for therapeutic proteins. In: Zhouand H, Meibohm B, editors. Drug-Drug Interaction for Therapeutic Biologics; 2012.
67. Drug Interaction Studies-Study Design, Data Analysis, Implications forDosing, and Labeling Recommendations (Draft Guidance). http://wwwfdagov/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm121568htm; 2012.
68. Shen BQ, Bumbaca D, Saad O, Yue Q, Pastuskovas CV, Khojasteh SC, Tibbitts J, Kaur S, Wang B, Chu YW, Lorusso PM, Girish S. Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine T-DM1: An emphasis on preclinical and clinical catabolism. Curr Drug Metab; 2012.
69. Koren E, Smith HW, Shores E, Shankar G, Finco-Kent D, Rup B, Barrett YC, Devanarayan V, Gorovits B, Gupta S, Parish T, Quarmby V, Moxness M, Swanson SJ, Taniguchi G, Zuckerman LA, Stebbins CC, Mire-Sluis A. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods. 2008;333:1-9.
70. Putnam WS, Prabhu S, Zheng Y, Subramanyam M, Wang YM. Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies. Trends Biotechnol. 2010;28:509-16.
71. Peng K, Siradze K, Quarmby V, Fischer SK. Clinical immunogenicity specificity assessments: A platform evaluation. J Pharm Biomed Anal. 2011;54:629-35.
72. Guidance on Immunogenicity Assessment of Biotechnology-Derived Therepeutic Proteins Draft. wwwemaeuropaeu/pdfs/human/biosimilar/1432706enpdf; 2007.
73. Morgan P, Van Der Graaf PH, Arrowsmith J, Feltner DE, Drummond KS, Wegner CD, Street SD. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug discovery today; 2011.
74. FDA. International Conference on Harmonisation Guidance for Industry: E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. http://www.fda.gov/RegulatoryInformation/ Guidances/ucm129335.htm (accessed 10 Feb 2012.
75. Zandvliet AS, Schellens JH, Beijnen JH, Huitema AD. Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology. Clin Pharmacokinet. 2008;47:487-513.
76. Tabernero J, Pfeiffer P, Cervantes A. Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: An effective, more convenient alternative to weekly administration? Oncologist. 2008;13:113-9.
77. Jumbe NL, Xin Y, Leipold DD, Crocker L, Dugger D, Mai E, Sliwkowski MX, Fielder PJ, Tibbitts J. Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice. J Pharmacokinet Pharmacodyn. 2010;37:221-42.
78. Naumovski L, Junutula JR. Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer. Curr Opin Mol Ther. 2010;12:248-57.
79. Deng R, Iyer S, Theil FP, Mortensen DL, Fielder PJ, Prabhu S. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: What have we learned? mAbs 2011;3:61-6.
80. Ling J, Zhou H, Jiao Q, Davis HM. Interspecies scaling of therapeutic monoclonal antibodies: Initial look. J Clin Pharmacol. 2009;49:1382-402.
81. Leipold D, Bender B, Keyang K, Theil F, Tibbitts J. Understanding the de-conjugation ofTrastuzumab-MCC-DM1through application of a multi-compartmental model of individual drug: Antibody species in cynomolgus monkey. AACR Meeting Abstracts, Apr 2009; 2009: 2914; 2009.